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Abstract
The proliferation of medically assisted reproduction (MAR) for the treatment of infertility has brought benefit to
many individuals around the world. But infertility and its treatment continue to be a cause of suffering, and over
the past decade, there has been a steady growth in a new global market of inter-country medically assisted
reproduction (IMAR) involving ‘third-party’ individuals acting as surrogate mothers and gamete donors in
reproductive collaborations for the benefit of other individuals and couples who wish to have children. At the same
time there is evidence of a double standard of care for third-party women involved in IMAR, violations of human
rights of children and women, and extreme abuses that are tantamount to reproductive trafficking. This paper is
the report of an inter-disciplinary working group of experts who convened in Israel to discuss the complex issues
of IMAR. In Israel too IMAR practices have grown rapidly in recent years, mainly because of restrictions on access
to domestic surrogacy for same sex couples and a chronically insufficient supply of egg cells for the treatment
of couples and singles in need. Drawing upon local expertise, the paper describes documented practices that are
harmful, suggests principles of good practice based on an ethic of care, and calls for action at the international,
national and professional levels to establish a human rights based system of international governance for IMAR
based on three regulatory models: public health monitoring, inter-country adoption, and trafficking in human
beings, organs and tissues.
Keywords: Medically assisted reproduction, Cross-border reproductive care, Reproductive ethics, Human trafficking,
Surrogacy, Egg donation, Ethic of care, Human rights
Preface: an emerging global market
The proliferation of medically assisted reproduction
(MAR) for the treatment of infertility has brought
benefit to many individuals around the world, since the
first birth of a child following in vitro fertilization (IVF)
in 1978. By 2012 it was estimated that the number of
babies born as a result of MAR reached a total of
5 million [1]. Infertility is often a cause of suffering and
of social harm, particularly to women, and the right to
reproductive health can be understood to include a right
to treatment of infertility. But women also carry the
primary burden of treatment for others: IVF is used for
the treatment of male infertility; IVF also serves as a
platform technology for pre-implantation genetic diag-
nosis (PGD) of embryos, often with no medical cause
and as a tool for elimination of female fetuses. All these,
together with the spread of egg ‘provision’1 practices and
surrogacy arrangements, mean that more often than not
otherwise healthy women undergo invasive medical
interventions for the sake of their partners or for
strangers who wish to become parents.
What is more, over the past decade, there has been a
steady growth in a new global market of cross-border
medical travel for repro-genetic purposes. Many prac-
tices of inter-country medically assisted reproduction
(IMAR) involve ‘third-party’ individuals acting as surro-
gate mothers and gamete providers in reproductive
collaborations for the benefit of other individuals and
couples who wish to have children. IMAR involves
various permutations of the cross-border movement of
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intended parents, third-party reproductive collaborators
and new-born children, with transfers of human em-
bryos, sperm and egg cells. Like transnational organ
transplants, IMAR consists of shifting international
networks. The chain of medical production starts from
sperm and egg cell procurement, and continues through
fertilization, embryo implantation and gestation, to
culminate in birthing. Theoretically each of these six
links could be performed in a different country, and the
child then transported to the country of the intended
parents. Some of the surrogacy practices currently
marketed involve, in combination, three different
provider countries. The intended parents from country
A might transact with an egg provider from country B,
who travels to a clinic in country C, where the egg is
fertilised and implanted in a surrogate mother from
provider country D (Eyal H, Samama E, Shalev C.
Transnational surrogacy and the earthquake in Nepal: a
case study from Israel. In: Miranda Davis [ed], Global
Babies: Transnational Surrogacy and the New Politics
of Reproduction (Zed Books, forthcoming 2017)).
The growth of the IMAR market in recent years is due to
complex economic, legal and cultural conditions. A major
driver of this multi-billion dollar business is the desire of
individuals to parent children, and their inability to do so in
their home countries due to legal restrictions or economic
constraints on surrogacy or egg cell procurement. More-
over, there are signs of an emerging market of cross-border
reproductive care for non-medical sex selection of embryos
by means of PGD, and similar practices for the selection of
preferred embryonic traits are likely to grow further [2].
Since the IMAR market is not regulated, there is no official
data and a dearth of information. At the same time,
for-profit trade in IMAR services involves the commodifi-
cation of human beings (women and children) and body
parts (gametes and wombs). Indeed, there is evidence of
violations of the human rights of children and women, and
some cases of harmful and degrading practices have been
documented [3].
Against this background, an interdisciplinary group of
ethicists, researchers and practitioners convened in
Israel to discuss the need for international governance of
IMAR (for a list of the participants, see Additional file 1).
Israel is a country in which MAR is practiced extensively
with almost unlimited public funding, resulting in the
highest per capita rates of usage worldwide [4]. Courts
recognize a constitutional right to parenthood, and the
Knesset, Israel’s parliament, has enacted legislation that
establishes a regulatory system of bureaucratic approvals
for various third-party MAR practices, based on statutory
criteria of eligibility. Israel’s Surrogate Mother Agreements
Law (1996), was the first in the world to allow commercial
surrogacy under the supervision of a statutory committee
[5, 6]. The Egg Cell Donations Law, 2010 enacted a similar
system [7]. Nonetheless, despite liberal domestic law,
IMAR practices have grown rapidly in recent years,
mainly because of restrictions on access to domestic sur-
rogacy for same sex couples [8] and a shortage of healthy
women who are willing to provide their eggs for the
treatment of couples and singles in need [9]. Although the
Egg Cell Donations Law allowed ‘donations’ from healthy
volunteers and compensation for their effort, it did not
alleviate the ‘shortage’ of egg cells in the country. Therefore
Israel, despite its relative small population size, has become
an important site for gathering information regarding the
complex mechanisms of IMAR usage, and indicates the
urgent need for agreements and regulations that will ensure
the health and well-being of all collaborators.
This document is based on our collective experience
and knowledge. Our discussions revealed differences of
opinion that reflect multiple perspectives on the com-
plex issues of IMAR, even among professional re-
searchers who are all committed to a human rights
based approach. We discovered, inter alia, different con-
cepts of autonomy, different views as to the degree to
which the State should interfere in agreements between
consenting adults, and different opinions as to the
proper balancing of competing rights and values. But by
all indications the issues are here to stay, and will likely
grow as new business opportunities emerge to bring to
the IMAR market controversial technological innova-
tions, such as the recent developments of mitochondrial
replacement therapy, and whole genome sequencing or
CRISPR-Cas9 (‘gene editing’) for embryos [10].
The purpose of this paper is to call for a discussion of
the need for IMAR international governance at multiple
levels – the international community, nation states, pro-
fessional organizations and civil society – as market
forces lead the proliferation of reproductive technologies
for individuals of means.
The subject matter is extremely controversial. Questions
of children’s legal parentage and nationality in transnational
surrogacy have been on the agenda of the Hague
Conference on Private International Law for several years. A
comprehensive document prepared by its Permanent Bureau
in 2014 notes the diversity in states’ domestic law regarding
the establishment of legal parenthood, and emphasises the
importance of focusing on building bridges between legal
systems based on internationally established common
principles, rather than the harmonisation of substantive laws
concerning legal parentage [11]. Yet discussions there have
yet to resolve the divergent views on the legal status of
children born in cross-border situations that circumvent
legal prohibitions in the parents’ country of origin [12].
What is more, public international law aspects of
IMAR practices that are similar to the field of organ
transplant tourism, such as trafficking in human beings
and body parts [13] – are not within the mandate of the
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Hague Conference, and have not been addressed so far
by any other relevant international forum.
The goal of this paper is to set an agenda for discus-
sion, to identify areas of concern, to suggest good prac-
tices that might alleviate some of the most grievous
consequences of an unregulated IMAR market, and to
describe points of disagreement that require further ex-
ploration. The paper concludes with a call for action at
the international, national and professional levels within
the framework of a feminist ethic of care for all involved
individuals, including the children and the women who
assist in bringing them into the world. We believe that
continuing discussion and deliberation will eventually
lead to clarity as to the promotion of fair practices, the
prevention of human rights violations and the
criminalization of extreme abuses.
Terminology
Much of the literature on the subject of IMAR refers to
“cross-border reproductive care”. This reflects the view-
point of individuals suffering from infertility who need
and seek access to medical treatment which is either un-
available or unaffordable in their countries of origin. We
chose to use the term “inter-country MAR” because it
accommodates the viewpoints of all involved individuals,
including the third-party reproductive collaborators.
Moreover, we refrain from using the term ‘care’ which
carries underlying assumptions of altruism and empathy,
which is not necessarily present in the medical interven-
tions involved in medically assisted reproduction, espe-
cially when involving third-party reproductive laborers.
Similarly, much of the literature addressing domestic
issues refers to ART (“assisted reproductive technol-
ogy”), rather than MAR (“medically assisted
reproduction”). We chose the latter, because it reflects
the human activity of reproduction, whereas the former
focuses on the technology.
Human reproduction by its very nature involves the
collaboration of human beings, in particular women,
whether or not medically assisted, and whether or not it
involves third-party individuals. The notion of collabor-
ation implies respect for all those assisting in the birth
of the child. Because reproduction is essentially collab-
orative, we use the term “third-party collaborators” to
denote the genetic progenitors (gamete “providers”) and
the women who carry pregnancies and give birth to
children (“surrogate mothers“) for other individuals
whom we call the “intended parents”.
The term “providers” is used for those whose gametes
(egg cells and sperm) are used in the reproductive
collaboration, so as to preserve the term “donors” for
those who act altruistically in non-commercial relation-
ships, and “procurement” rather than “donation” is used
for the same reason.
Ethics and human rights
Our theoretical approach is a human rights based ethics
of care and responsibility. As opposed to transnational
transplant medicine, where professional self-governance
provided the basis for an emerging consensus in inter-
national law, IMAR remains an unregulated market
driven by the desire of prospective parents for a family
and a healthy child and the profit making interests of
medical entrepreneurs and the biotechnology industry
[14]. At the moment, there are no internationally ac-
cepted ethical principles or clinical standards for the
quality and safety of MAR interventions. The distribu-
tion of scarce human bio-resources is done according to
ability to pay rather than considerations of justice or
solidarity [14, 15]. There are no mechanisms in inter-
national law for transparency and accountability, nor for
regulatory oversight in case of human rights violations.
And lastly, there is no understanding of what differenti-
ates legitimate cross-border medical travel from repro-
ductive trafficking, and no criminal justice redress for
instances of exploitation, deception and coercion [13].
MAR has brought many blessings to numerous indi-
viduals worldwide, but in some cases this has incurred
harm to other individuals. The main approach of this
paper is to suggest good practices so as to avoid harm to
children and third-party women and men. But we also
acknowledge known cases of such harm and argue for
the need to prohibit the most grievous harmful practices
as tantamount to reproductive trafficking.
Our view comes from a commitment to an ethic of care
and responsibility, respect and solidarity towards all the
adults involved in IMAR collaborations, concern for the
rights and well-being of the resultant children, and a com-
mitment to inter-generational justice and responsibility for
the heritage of humanity that we pass on to future genera-
tions [16]. We align our call with concerns brought to the
fore by feminist scholars in recent decades [17, 18], while
also recognizing the agency of reproductive labourers and
the need for their involvement in the discussion, as sug-
gested by ethnographies of the reproductive trade [19–21].
Our view is that the activity of reproduction is intrinsically
dependent on collaboration with others, and the relational
context of this activity should be acknowledged so as to
avoid the objectification of third-party collaborators. We
believe that it is in the child’s best interests to be born from
and into relationships, however short- or long-lived, that
are based on respect, reciprocity, trust and integrity be-
tween intended parents and third-party collaborators [22].
The working group reaffirmed its commitment to
values of fundamental human rights and the dignity and
worth of the human person. These include the equal
rights of men and women, regardless of race, class,
marital status and sexual identity. Multiple instruments
of international human rights law contain principles and
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rules that are relevant to IMAR, including the right of
adult men and women to found a family, the right of
women to reproductive health, the right of persons to
autonomy in medical decision making, and the right of
children to identity, parentage and nationality [23–26].
(For further detail on relevant instruments of inter-
national human rights law, see Additional file 1).
However, none of those instruments address the po-
tential for the exploitation, coercion and deception of
women as providers of reproductive services and re-
sources. There is a consensus that human beings and
their body parts cannot be the subject of commercial
transaction and financial gain [27–33]. But issues of
third-party IMAR practices are not addressed in the
relevant instruments that prohibit servitude and traffick-
ing in human beings and organs, while instruments on
tissues and cells typically exclude the cross-border trans-
portation of human sperm, egg-cells and embryos [13].
A common argument in defence of the MAR market
derives from the principle of personal liberty and free-
dom of contract [34]. However, much as personal liberty
is inalienable and cannot extend to the right of an indi-
vidual to sell one self into slavery [35, 36], and much as
freedom of contract is constrained by considerations of
morality and public policy, the freedoms and rights of
infertile persons to establish a family through IMAR
may be subject to limitations for the purpose of meeting
just requirements of morality and public order in the
global marketplace. Such restrictions are necessary and
justified out of respect for the rights and freedoms of
both the children and the third-party women who pro-
vide their bodily services and resources to assist in
bringing them into the world [37].
Areas of concern
IMAR is a particular form of medical tourism but it raises
concerns beyond those which are typical to critiques of
general medical tourism practices, such as quality of care,
and the issues of affordability and accessibility which con-
cern distributive justice in two-tier health systems [38–40].
Unlike most situations of cross-border medical care, IMAR
also involves the use of another (non-patient) person’s
body as a means of medical “treatment”. In this it is similar
to transnational organ transplant procedures. We therefore
believe that our discussion aligns better with bioethical
discussions of organ transplant medicine in cross-border
settings. Furthermore, IMAR also involves the creation of a
child, and thus aligns with inter-country adoption as well
as the literature examining the commodification of human
bodies and intimacies more broadly.
Intended parents
Despite the many benefits of MAR in alleviating infertil-
ity, the proliferation of this technology has led to
multiple new forms of associated suffering. Despite the
many children born to otherwise infertile persons by
means of MAR, infertility as such continues to be experi-
enced as distressful and socially stigmatized. Childlessness
may be remedied, but people want more than one child.
In addition, infertility treatment itself is physically and fi-
nancially taxing and often entails multiple unsuccessful
cycles. Emotional harms associated with infertility treat-
ment include anxiety and grief, as well as stress and dis-
ruption of spousal relations, shame and blame, anger and
depression, low self-esteem and stigma [22]. The suffering
of the thwarted desire for a child may be aggravated by
limitations on access to treatment for couples and individ-
uals in need due to the lack of available or affordable
services. In 2011 only 48 out of 191 member States of the
World Health Organization had IVF facilities. Among
those that do, many do not have insurance schemes for
reimbursement for MAR treatment [41].
At the same time, success rates remain relatively low:
pregnancy rates per treatment cycle are around 35%,
with around 25% chance of a live birth per treatment
cycle [42]. Risks to the health and well-being of women
from preparatory hormonal treatment, egg retrieval and
multiple embryo-pregnancies are well known [43].
Multiple-embryo pregnancies are also associated with
premature delivery and low birth weight new-borns.
Moreover, infertility patients seeking treatment outside
their home countries might be at increased risk due to
lack of control over quality and safety standards; the
absence of counselling; inadequate information about
possible health risks; and increased exposure to incom-
petence, negligence and recklessness [44].
In the case of third-party IMAR, intended parents are
vulnerable to disinformation and exploitation by inter-
mediaries in foreign countries. Added risks include
uncertainty as to the source of gametes or embryos, and
financial extortion by intermediaries who might also
obstruct attempts to contact, deal directly and form a
relationship with surrogate mothers. In addition there
are numerous bureaucratic hurdles to establishing par-
entage and returning home with the children [45].
Third-party collaborators
As for egg cell providers and surrogate mothers, a major
concern is the exacerbated risk of harm from medical
interventions because of a double standard of care, that
is, care that is centred towards the paying customer
rather than the surrogate’s or egg donors’ medical needs,
as well as emotional and financial harm due to unequal
relations of power between third-party collaborators and
commissioning parents, and the potential bias of media-
tors and professionals within the IMAR industry.
Physical risks to egg cell providers include the pain
and discomfort of daily hormonal injections and harmful
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side effects, including anaesthesia complications, ovarian
hyper-stimulation syndrome, damage to reproductive or-
gans and post-retrieval complications of surgery [46]. Re-
cruitment advertisements on university campuses do not
mention these risks, and the women might undergo exces-
sive repeat procurement cycles without being informed of
the risks involved [47]. Although there has been no
systematic medical tracking of the effects of egg cell pro-
curement on otherwise healthy young women, there is no
evidence base for the safety of the procedure in the med-
ical literature, and there are controversies regarding long-
term risks of breast and ovarian cancer [48]. Anecdotes
abound of loss of fertility, stroke, cancer and premature
death, while psychological risks of detachment from re-
sultant children might arise years later [49, 50].
The potential for exploitation and deception of women
who provide egg cells for others is illustrated by a case from
Israel that came to light in 2000: a leading fertility expert
confessed in professional disciplinary proceedings to having
submitted patients to excessive hormonal stimulation,
retrieving dozens of eggs from single treatment cycles, and
using these eggs in the treatment of large numbers of
recipients, without the knowledge of the providers. In one
case he retrieved 256 eggs from one woman and used 181
of them to treat 34 others [7, 51].
Research from Israel on domestic surrogacy agreements
reveals similar vulnerabilities of third party women to a
double standard of medical care and disinformation, and
also to emotional harms and violations of privacy and au-
tonomy. Israel provides a rich data source on commercial
surrogacy, since the Surrogate Mothers Agreements Law
(1996) requires approval of any surrogacy contract signed
and performed within the country. It is therefore possible to
know exactly how many surrogacy contracts were signed
since 1996 and their outcomes. Data collected from official
records of approved surrogacy agreements show a relatively
high rate of multiple births. Notably, less than 40% of the
agreements actually result in the birth of children, and com-
mercial practices often do not pay women for unsuccessful
treatment cycles, failed attempts to become pregnant or
spontaneous miscarriage of a pregnancy, while the women
report a heavy emotional toll of failure [8, 52]. Nor are the
women remunerated fairly for the time and energy they in-
vest in the process of applying for bureaucratic approval, in-
cluding intrusive mental and physical diagnostic procedures
[52]. In the case of a successful pregnancy, agreements typ-
ically restrict the surrogate’s lifestyle and personal freedom,
with obligations to refrain from sexual intercourse, not to
smoke, not to eat certain foods, and a requirement to obtain
permission from the intended parents to travel outside the
country, thus limiting their personal autonomy beyond what
would be expected in the case of women carrying their own
child. Surrogate mothers, like egg providers, appear to be
motivated by both financial interests and noble altruistic
sentiments, and report forming an emotional attachment
with the intended parents during the pregnancy, often with
a sense of self-worth as a result of this relationship, which
allows them to experience the process as an act of heroism
rather than exploitation [53]. But once they deliver the child
this relationship might be severed abruptly and surrogates
report having little control over the process of separation
after having given birth [8].
The vulnerability of third-party reproductive collaborators
to harm is exacerbated in inter-country settings due to struc-
tural inequalities, geographical distance and cultural gaps.
There is limited quantitative data, because IMAR takes place
in a private market. But social science studies, human rights
reports and documentary films – mostly about India – indi-
cate patterns of exploitation, deception and coercion that
might amount to human trafficking [13]. Cases in which
women have been recruited to travel and tricked or forced
into working as surrogates have been documented in
Guatemala, Poland, Myanmar and Thailand [54]. In more
routine cases, intended parents may set in course a process.
marketed and facilitated by intermediaries, that culminates in
the birth of a child without having met or seen their third-
party collaborators. The relative invisibility of resource pro-
viders to those who purchase gametes or surrogacy services in
these markets, due to language and cultural barriers as well as
geographical and social distancing, is a factor that objectifies
them and diminishes concern for their well-being [22, 45].
Egg providers are typically recruited to be a racial match
with intended parents, but do not receive any information
about their identity. International surrogacy agencies work-
ing from Israel recruit women from countries such as the
Ukraine and South Africa, offering them a “reproductive
tourism” package that includes egg “donation” and a holi-
day in India, Thailand or Nepal. Women in India will pro-
vide eggs for intended parents who are Indian, whether
residing in or outside the country. These women might also
work as surrogates and as human subjects in clinical trials.
One woman who provided eggs recounted that the hospital
told her to get lost after the retrieval procedure and refused
to give her any medical record of the intervention [55].
Surrogacy practices in India incur impaired autonomy in
decision making about the pregnancy: choices about the
numbers of embryos implanted, termination of pregnancy,
lifestyle during pregnancy, and interventions during labour
and delivery such as c-section will be made by the intended
parents and medical professionals. The literature describes
deprivations of liberty (confinement in hostels for the
duration of the pregnancy, with controlled nutrition and
limited family visits), violations of patient autonomy and
bodily integrity (non-consensual abortions, routine c-
sections) and exploitation of maternal labor (multiple
embryo implantations, and breast milk nursing pending the
late arrival of intended parents). Social harms include
stigmatization [3, 56–59].
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In many cases, surrogate women are required to leave
their homes and live in dormitories or housing providing
by the surrogacy clinics and agencies. These practices have
been documented in India [55, 59–61], Nepal (Eyal H,
Samama E, Shalev C. Transnational surrogacy and the
earthquake in Nepal: a case study from Israel. In: Miranda
Davis [ed], Global Babies: Transnational Surrogacy and the
New Politics of Reproduction (Zed Books, forthcoming
2017)) and Russia [62]. In such dormitories or housing ar-
rangements, surrogates are fed and monitored around the
clock by the clinic personnel, and in extreme cases are not
allowed to exit the site or engage in physical activity [3, 55,
59, 60]. One of the narratives is about a surrogate awaiting
the arrival of the intended parents, an Indian couple from
Canada, after giving birth to twins. After delivery, she ex-
presses breast milk to feed the babies. Ten days after the
birth the parents have still not come and she ventures into
the infant unit to see the babies. As time goes by and the
parents still do not come, she starts physically taking care
of the infants and names them. The couple arrive only
three weeks after the babies were born [60].
While the standard of care for MAR in developed coun-
tries now discourages the implantation of multiple embryos
because of the risks to the health of the pregnant woman
and to premature newborns, it is often practiced in IMAR
[61]. Surrogates are usually offered a bonus payment for
carrying and giving birth to twins, but if more than two
embryos develop they are expected to undergo a procedure
of embryo reduction to abort the excess one [3, 61, 63].
Accounts of intended parents from Israel stranded in
Katmandu with their newborns at the time of the
earthquake there in May 2015, indicated relatively large
numbers of twins and premature births. The clinic there
had a 100% rate of c-sections, which the women were told
was the “best way” to give birth – yet another instance of
a double standard of medical care. Of course, c-section
allows for control over the time of the birth of the child,
so that intended parents can plan travel accordingly.
According to the accounts of intended parents, their
expectation was that the children would be born at 36
weeks, rather than 40, which is the norm (Eyal H, Samama
E, Shalev C. Transnational surrogacy and the earthquake
in Nepal: a case study from Israel. In: Miranda Davis [ed],
Global Babies: Transnational Surrogacy and the New
Politics of Reproduction (Zed Books, forthcoming 2017)).
A business model that guarantees an end product and
caters to the preferences of customers has also led to
what is known as ‘twin’ or ‘twibling’ surrogacy, where
two surrogate mothers are hired at the same time in
order to maximize the chance of a live birth [64]. At a
‘surrogacy fair’ in Israel, in February 2013, attended by 15
surrogacy agencies from Israel and the USA, one agency
offered potential customers a track of ‘parallel pregnan-
cies’ in which several women would carry pregnancies for
a single prospective family, so as to increase the chance of
producing a child within a certain time frame. It was im-
plied that if the achieved pregnancies exceeded the
planned number of children, the ‘excess’ pregnancies
would be terminated. The women carrying the aborted
pregnancies have no say in the decision. They might be
deceived and told that there is a medical indication related
to the health of the foetus. According to one surrogacy
agent operating in Eastern Europe, under their contract
surrogates might not be entitled to payment for their ser-
vices if a live child is not produced.
Children
While the number of children conceived as a result of
inter-country surrogacy and other IMAR arrangements
has increased dramatically in recent years, there have been
certain extreme cases of child trafficking in which the
babies have become commodified as a marketable product
of exchange [54]. For example, the surrogacy industry in
India has also produced ‘extra’ babies, either because
excess pregnancies are carried to full term or because
intended parents do not claim the children they ordered.
At this point the abuse of surrogate mothers turns into
baby selling. In a recent documentary, one journalist went
undercover to meet a surrogacy agent who claimed there
were ‘extra’ babies being sold on the black market, and
there and then offered to sell her one on the spot [65, 66].
In February 2012, Theresa Erickson, a USA attorney
specializing in reproductive law was sent to prison for her
role in an international baby selling scheme. In her guilty
plea, Erickson admitted that she and her conspirators used
surrogate mothers to create an inventory of unborn babies
that they would sell for over $100,000 each. They accom-
plished this by paying women from the USA to travel to the
Ukraine, to become implanted with ‘donated’ sperm and eggs.
If the women sustained their pregnancies into the second
trimester, the conspirators offered the babies to prospective
parents by falsely representing that the unborn babies were
the result of legitimate surrogacy arrangements, but that the
original intended parents had backed out [67, 68].
A recent decision of Israel’s Supreme Court ruled that a
genetic connection between the child and at least one of the
intending parents is needed in order to rule out child
trafficking. The case concerned a single woman who
arranged for the fertilization of embryos with the sperm of
an acquaintance and the egg cell of an anonymous provider
from South Africa. The woman’s niece carried the preg-
nancy for her after undergoing embryo implantation in
India, and gave birth to the child in Israel. The woman then
petitioned the court for a parenting order, which she was
denied. The court reasoned that the law does not recognize
parentage that is purely contractual, and making babies
cannot be left to simple agreement for the creation of
a product [69].
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In other cases children born of IMAR have been ren-
dered parentless and stateless, in violation of the rights
of the child to nationality and parentage under article 7
of the Convention on the Rights of the Child [70, 71].
The baby is born in one country on the basis of an
agreement with the intended parents who live in an-
other, and they need travel documents to bring the baby
home. But conflicts of domestic law can arise between
the two jurisdictions as regards the determination of
legal parenthood. In one case, intended parents from the
UK had a child from surrogacy in the Ukraine. Under
the law in the UK the surrogate and her husband would
be considered the legal parents, while under the law in
the Ukraine the child’s legal parents were the intended
parents, so they could not adopt the child to be recog-
nized as her parents under UK law.
In another case, the European Court of Human Rights
found that France had violated the right of children born of
international surrogacy to respect for private family life
under Article 8 of the European Convention on Human
Rights, by denying the parent–child relationship that had
been legally established in the USA, where the children were
born. The decision concerned two couples from France
who had children biologically related to the male partner by
means of a surrogacy agreement in the USA, where the legal
parent–child relationship had been recognized. The French
authorities refused to enter the birth certificates in the
French register of births, because that might be seen as
giving effect to a surrogacy agreement that was null and
void under French law on grounds of public policy [72].
Other cases have involved abandonment of the children.
For example, an infant was born in India in 2010 to a mar-
ried couple from Japan, who had divorced during the
course of the pregnancy. Neither the Indian birth mother
nor the Japanese intended mother wanted the child. At
the time Japanese law did not recognize surrogacy and the
intended father could not adopt the child under Indian
law because he was now single. The baby’s paternal grand-
mother took responsibility for the baby but they were
stranded in India for six months while trying to overcome
the legal hurdles to obtaining travel documents (Margalit,
Yehezkel. From Baby M to Baby M(anji): Regulating
international surrogacy agreements. J Law Policy.
Forthcoming) [71, 73]. A more recent and much publi-
cized case was that of Baby Gammy born as a twin in
Thailand in 2014 to an Australian intended couple.
Gammy had Down’s syndrome and a congenital heart
condition, and the intended parents took his healthy twin
sister home while abandoning him. The Thai surrogate
mother took responsibility for Gammy, and succeeded
eventually in obtaining Australian citizenship for the child
and rights of access to health care in Australia [74].
Yet another crucial issue concerns the right of the
child to identity, or the right to know the circumstances
of one’s birth and origin. This has both psychological
and health-related aspects. Medical documentation
about genetic progenitors is obviously relevant to in-
formed health care decision-making, but the right to
know has more far-reaching meaning as is evident from
the growing support for the moral right of donor-
conceived children to know their genetic origins [75]. It
is a key facet of the child’s sense of self-identity and his
or her connectedness with heritage and kin, be they the
genetic father and mother, the woman who gave birth,
or part-siblings. But in IMAR no one has the legal obli-
gation or responsibility to keep records of gamete pro-
viders and surrogate mothers. This erases the identity of
the third-party collaborators while compromising the
child’s ability to learn of his or her circumstances of
birth later in life.
Discussion
Arrangements between intended parents and third-party
reproductive collaborators create a special kind of agree-
ment that needs regulation so as to protect the interests
of all the involved persons: the intended parents, the
third-party collaborators and the children. In inter-
country settings, under conditions of geographical dis-
tance and cultural disparity, the for-profit motivation of
medical entrepreneurs and intermediary agents exacer-
bates the potential commodification of women and chil-
dren. The unregulated market of IMAR involves the
commercialization of human reproduction and trans-
forms the personal and intimate nature of reproductive
relations into contractual and labour relations. Consider-
ing also foreseeable technological developments that
would allow the genetic selection and modification of
human embryos, there are profound concerns about the
moral limits of markets and the impact of market-driven
repro-genetic technology on the future of humanity and
the very nature of the human species.
In inter-country settings, the current lack of profes-
sional self-governance and the absence of internationally
accepted clinical-ethical guidelines for MAR are condu-
cive to potential abuse of third-party women who
collaborate to fulfil the desire of others to have a child -
throughout the process of egg cell extraction, fertilization,
impregnation, implantation, gestation, miscarriage,
labour, delivery and post-birth nursing and care. These
women are often treated according to double standards
of care for invasive medical interventions, ethical
standards of consent to treatment are not observed, and
decisions about the medical interventions they undergo
are often made by others. At times they have no direct
contact with intended parents and do not even know who
they are. Intermediaries perform a necessary social
function in mediating between individuals seeking
MAR services outside their countries of residence.
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However, the commercial nature and profit-seeking
motivation of this function create conditions that are
conducive to exploitation.
There is evidence that unregulated IMAR can lead to
grave violations of women’s dignity and human rights, as
described above. In extreme circumstances, abuses
might even amount to human trafficking, in the sense of
the appropriation and control of women and children as
commodities. Thus, there is an urgent need to conceive
a governance regime for the unregulated IMAR market
so as to ensure safe and fair practices, minimize harms
and prohibit abuses.
IMAR need not necessarily be abusive or incur viola-
tions of human rights. Lessons learned from countries in
which MAR is regulated indicate elements of a good
practice model by which new forms of multi-parent fam-
ilies can be established on the basis of mutual respect,
intimacy and relationship between intended parents and
reproductive collaborators, with support and counselling
for all the involved adults throughout the process. Most
of the participants in the working group of Israeli ex-
perts thought that open relationships between third-
party collaborators and the children and their families
could be encouraged, and the altruistic motivations of
third-party collaborators could be acknowledged even if
they are also paid for their work. Some thought that fully
altruistic arrangements should be seen as best practice,
i.e., where the egg donor or surrogate mother is a rela-
tive or friend of the intended parents. In such case, how-
ever, it would be necessary to ensure that the women are
not induced to collaborate as a result of family or social
pressure, and that they are fully informed of the risks in-
volved in the process and provided with compensation if
these risks should materialize.
One view in the literature [45] is that ideally countries
might aim to adopt a policy of national self-sufficiency
so as to meet domestic needs for MAR, including third-
party reproductive collaborations, and to minimize dis-
incentives to local providers of gametes and surrogacy
services such as lost wages, costs of travel and out-of-
pocket expenditures. Nonetheless, international govern-
ance is needed since it is improbable to assume that the
global market will disappear.
First and foremost, international bodies and nation
states should recognize new forms of family and should
guarantee the child’s right to parentage, nationality and
identity. Some of the working group participants consid-
ered that responsibility for the welfare and best interests
of children born of IMAR should be paramount. There-
fore, in case of conflicts of law as regards the child’s
parentage, the default presumption should be that the
country of birth is parens patriae, in accordance with
the principle of subsidiarity. Likewise, this view sug-
gested that children born of IMAR should have a right
to nationality in both the country in which the intended
parents are nationals and the country of birth. This
would prevent the child from being rendered stateless in
case of dispute about the child’s parentage and make it
the responsibility of both countries to care for children
born of reproductive collaborations initiated by their na-
tionals, or within their jurisdictions.
As for the right to identity of children born of IMAR,
i.e., the right to know the origins of conception and cir-
cumstances of birth for both medical and psychological
needs, the consensus among the working group was that
the medical professionals who administer the procedures
that result in the child’s birth should have a legal obliga-
tion to preserve identifying information about the third-
party collaborators.
However, there was disagreement about whether or
not children have a right to know the identity of their
genetic progenitors, as in adoption, and whether or not
they have a right to know the identity of their gestational
mother. One view was that the child has a medical inter-
est in knowing the identity of the genetic mother, but
does not have any interest in knowing the identity of the
woman who carried the pregnancy and gave birth if
there is no genetic relation between the two. Others
considered this view – that genetic motherhood is of
greater value than gestational motherhood – to be an
expression of genetic essentialism and materialism, and
to reflect a gender bias since genetic parenthood is the
only form of biological parenthood for the male of the
human species, as opposed to the female form of bio-
logical parenthood which can be either genetic or gesta-
tional. According to this point of view, epigenetics show
that the gestational environment has significance for the
child’s development, and female parenthood emphasizes
the nurturing aspect of human relationship.
What is more, the third-party collaborators also have
an interest in whether or not their identifying informa-
tion is preserved and made accessible to the children
[76]. The issue of the anonymity of third-party collabo-
rators is controversial. Its origin is in the practice of
sperm ‘donation’. Recognition of the children’s interest
in knowing the identity of their fathers has led some ju-
risdictions to legislate a right to disclosure for ‘donor’
offspring similar to the law of adoption. The members
of the working group were divided as to whether a
similar scheme should apply to egg cell procurement in
inter-country settings. Some considered that anonymity
was a compromise of parental responsibility and should
be discouraged. Others considered that it would not be
beneficial if disclosure of identifying information led to
a decrease in egg cell provision, and that potential
providers should be given the choice as to whether to
be anonymous or identifiable when the child reached
the age of majority.
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In any event, most participants thought there was a
difference between egg cell procurement and surrogacy,
and there was widespread agreement that anonymous
surrogacy should not be allowed because it violates hu-
man dignity. From the point of view of the woman who
carries the pregnancy and births the child, anonymity
and the erasure of any identifying information renders
her invisible, and is a means of objectification, com-
modification and instrumentalization that dehumanises
the person as a mere vessel. It is therefore important to
make sure the gestational mothers are present as human
beings, and they have a right to be acknowledged as hav-
ing birthed the children and to choose whether and how
to have ongoing contact with them.
There was also substantial agreement about drawing
red lines of extremely harmful IMAR practices that
should be prohibited as criminal offences under both do-
mestic and international law. Drawing parallels from
international documents on organ transplant trafficking
[27, 77, 78] these offences might include:
 medical interventions in third-party collaborators
without the free, informed and specific consent of
the patient;
 the use, storage and transportation of illicitly
procured human reproductive cells and embryos;
 the commercial brokerage of IMAR services,
including solicitation, advertisement and
recruitment of sperm and egg donors and surrogate
mothers for financial gain (i.e., advertisement and
brokerage involving payment);
 the implantation of human embryos outside of the
framework of the domestic regulatory system;
 the solicitation of gamete donors and surrogates to
cross national borders, for the purpose of evading
local protective regulations or undermining the rights
of reproductive labourers in their country of origin;
 the offer or receipt by health care professionals of
any undue advantage in connection with illicit
IMAR practices.
In general, countries of origin and destination should
take responsibility to quell the cross-border abuses of
women and children perpetrated by nationals in circum-
vention of domestic law. Ideally, they should not allow a
double standard of intra- and extra-territorial legality,
and would exercise extra-territorial jurisdiction over of-
fences committed by or against nationals or other indi-
viduals who are resident within their jurisdiction, in
contravention of domestic restrictions on access to
MAR [79, 80]. In this respect, the question whether
intended parents should be penalized for circumventing
domestic laws needs further consideration because it
involves possible stigmatisation of children with “new
illegitimacy”. However, intermediary agencies should be
held responsible.
Many participants in the working group took the pos-
ition that commercial intermediary agencies should be
banned and replaced by non-profit organizations with
the capacity to provide professional counselling, similar
to the model of the Hague Convention on Inter-Country
Adoption, 1993. The group was divided as to whether
individuals representing IMAR agencies currently oper-
ating out of Israel should be invited to participate in the
process of deliberation about the need for international
governance. Some thought that their experience and
knowledge of the field would be a valuable contribution
to the discussion, and that they too should adopt a code
of business ethics, while others considered that commer-
cial interests would skew the debate.
Call for action
In light of all the above, it appears to be time for a system
of international governance that addresses the challenges
that IMAR presents. The system should be based on hu-
man rights and promote universal access to MAR for the
treatment of infertility through the sharing of knowledge,
transfer of technology and publicly funded services [81],
and be based on a combination of three existing models of
regulation: (1) an international mechanism for monitoring
IMAR practices; (2) inter-country adoption; and (3) traf-
ficking in human beings, organs and tissues.
Existing mechanisms of international monitoring, such
as those operating within the UN human rights treaty
bodies, or for public health purposes within the WHO
Framework Convention on Tobacco Control, 2003 might
be adapted to the context of IMAR so as to guarantee the
collection and reporting of transparent data as follows:
 To report on adverse events affecting the health and
well-being of third-party women and children born
of IMAR;
 To ensure the provision of post-procurement, post-
implantation and post-birth clinical follow-up care
for third-party women;
 To gather epidemiological data on IMAR and enable
the conduct of longitudinal studies on the health
and well-being of children and of third-party
women;
 To collect information for the traceability of human
reproductive cells and embryos at both national and
international levels, so as to guarantee quality and
safety in the interests of public health [27, 30, 31, 33].
Regulatory measures drawn from the model of the
Hague Convention on Inter-Country Adoption would
require the accreditation of not-for-profit IMAR agencies,
so that services involving women as third-party
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reproductive collaborators are provided equally and fairly
with due transparency and accountability. Such measures
might also establish designated central authorities for
maintaining a national registry of IMAR children, gamete
providers and surrogates, in order to guarantee the right
of the children to access information regarding their gen-
etic origins and circumstances of birth.
A regulatory model based on international norms con-
cerning trafficking in human beings, organs and tissues
would likewise establish a transparent system of national
oversight by means of competent not-for-profit national
authorities with overall responsibility and accountability
for IMAR practices involving nationals, including trace-
ability [33]. It would also ensure standards of provider
and recipient safety through the accreditation of MAR
centres for gamete procurement and embryo implant-
ation, and establish rules of distributive justice that gov-
ern the transparent allocation of and equitable access to
limited medical services and human resources, including
human reproductive cells, according to evidence-based
clinical guidelines. An anti-trafficking approach would
call for cooperation between countries of origin, transit
and destination to adopt necessary measures to prevent,
protect and prosecute the exploitation, deception and
coercion of third-party reproductive collaborators and
the sale of children.
We, therefore, call upon the United Nations and other
inter-governmental organizations and their agencies,
international human rights bodies and international pro-
fessional associations, nation states and civil society, and
upon all concerned individuals – jointly and severally, to
take all possible measures to respect, protect and fulfil
the human rights of women and children involved in
IMAR, including the following:
 To take appropriate measures, at both national and
international levels, to prevent practices which lead
to the commodification of children and women;
 To criminalise IMAR practices which involve the
sale of human beings and their body parts and
resources, including human reproductive cells and
embryos;
 To prohibit IMAR practices that involve the
exploitation, deception and coercion of third-party
women and men, and other violations of equity,
justice and respect for their human dignity and human
rights [32], regardless of the victim’s consent [79, 82];
 To provide medical, psychological and social care
for the short- and long-term effects of MAR on the
physical and emotional health and well-being of
third-party women who provide their reproductive
resources for the benefit of others, and for the
recovery of victims of exploitation, deception and
coercion, and reproductive trafficking [83].
Perhaps most importantly, the working group consid-
ered that medical professionals are key links in the IMAR
industry, without whose involvement none of the harmful
practices would be at all possible. As opposed to the field
of organ transplantation, in the area of reproduction pro-
fessional organizations have not laid down clinical stan-
dards of efficacy, quality and safety, and have not taken a
leadership role in terms of ethical self-governance.
We therefore call upon professional medical associa-
tions to take a leading role of self-governance in advancing
the international regulation of IMAR, and to establish
clinical and ethical guidelines that set universal standards
of respect and care for women undergoing MAR treat-
ment worldwide. The medical profession should also take
responsibility to ensure the traceability of human gamete
donations and embryo implantations, and to preserve in-
formation necessary to realize the right of the child to
know his or her origins. And last but not least - to adopt
standards of conduct that sanction health care profes-
sionals who are involved in illicit IMAR practices.
Endnotes
1Since in most cases eggs and sperm are provided for
a cost, and providers are financially compensated for
their genetic materials, we refrain in this article from the
common usage of the term “donation” in reference to
these practices, and prefer the more neutral and accurate
term “provision” or “providers”.
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